We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+44.92%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$584M
AUM Growth
–
Cap. Flow
+$503M
Cap. Flow %
86.17%
Top 10 Hldgs %
71.5%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$40.8M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$32.8M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$24.1M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$23M
5
COGT icon
Cogent Biosciences
COGT
+$17.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 65.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNTK icon
1
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.1B
$155M 26.54%
+1,100,000
New +$141M
MDVL
2
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$44M 7.53%
+58,416
New +$40.8M
AVIR icon
3
Atea Pharmaceuticals
AVIR
$391M
$42.5M 7.28%
+1,016,688
New +$32.8M
SRPT icon
4
CALL
Sarepta Therapeutics
SRPT
$1.8B
$40.7M 6.97%
+238,600
New +$35.4M
CERE
5
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$29.3M 5.02%
+1,767,440
New +$23M
SYRS
6
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$28.7M 4.91%
+264,250
New +$24.1M
FATE icon
7
Fate Therapeutics
FATE
$332M
$23.6M 4.05%
+260,000
New +$16.1M
NTRA icon
8
Natera
NTRA
$38.4B
$18.7M 3.21%
+188,000
New +$15.7M
COGT icon
9
Cogent Biosciences
COGT
$6.74B
$18.2M 3.12%
+1,622,591
New +$17.8M
IOVA icon
10
Iovance Biotherapeutics
IOVA
$2.18B
$16.7M 2.86%
+360,000
New +$14.3M
RGEN icon
11
Repligen
RGEN
$8.35B
$15.8M 2.71%
+82,500
New +$15M
CSTL icon
12
Castle Biosciences
CSTL
$732M
$14.1M 2.42%
+210,000
New +$11.4M
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.11B
$14M 2.4%
+413,061
New +$11.9M
LUNG icon
14
Pulmonx
LUNG
$58.7M
$13.7M 2.36%
+199,122
New +$9.75M
APLS
15
DELISTED
Apellis Pharmaceuticals
APLS
$13.2M 2.25%
+230,000
New +$9.73M
NTLA icon
16
Intellia Therapeutics
NTLA
$1.59B
$12.2M 2.1%
+225,000
New +$8.17M
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$2.04B
$11.9M 2.03%
+858,032
New +$12.5M
ITOS
18
DELISTED
iTeos Therapeutics
ITOS
$10.9M 1.87%
+322,794
New +$8.55M
ITMR
19
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$9.97M 1.71%
+501,964
New +$10M
ARVN icon
20
Arvinas
ARVN
$528M
$8.49M 1.46%
+100,000
New +$3.45M
FRLN
21
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$7.76M 1.33%
+28,333
New +$7.12M
VIR icon
22
Vir Biotechnology
VIR
$1.59B
$7.37M 1.26%
+275,000
New +$8.94M
FDMT icon
23
4D Molecular Therapeutics
FDMT
$583M
$6.22M 1.07%
+150,000
New +$6.19M
APTO
24
DELISTED
Aptose Biosciences, Inc.
APTO
$6.17M 1.06%
+3,131
New +$7.36M
SPRY icon
25
ARS Pharmaceuticals
SPRY
$687M
$5.96M 1.02%
+128,572
New +$4.29M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q4 2020 Portfolio in Review

Q4 2020 is the first quarter with a 13F filing on record for Ally Bridge Group, which disclosed 30 positions worth $584M. Its ten largest holdings account for 72% of the portfolio.

Its largest position is MedAvail Holdings, Inc. Common Stock: 58,416 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets.

  • Ally Bridge Group's largest Q4 2020 buy was MedAvail Holdings, Inc. Common Stock: 58,416 shares worth $44M.
  • Ally Bridge Group's ten largest holdings make up 72% of its $584M portfolio in Q4 2020.
  • Ally Bridge Group disclosed 30 positions in Q4 2020, its first 13F filing on record.

Based on Ally Bridge Group's 13F filing for Q4 2020, filed 16 Feb 2021.